Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.Rapidly Accelerated Fibrosarcoma is referred to as RAF. The RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade, involves Raf kinases. Interaction with RAS-GTPases is necessary for RAF kinase activation. A-RAF, B-RAF, and C-RAF (Raf-1) are the three members of the RAF kinase family. The B-Raf protein is involved in transmitting signals within cells that control cell growth.It was demonstrated that it was flawed (mutated) in a few human cancers. The RAF1 gene in humans encodes the enzyme C-RAF, also known as Raf-1. The c-Raf protein is a MAP kinase kinase (MAP3K) that works after the Ras subfamily of membrane-associated GTPases. It is a component of the ERK1/2 pathway. C-Raf is a member of the TKL (Tyrosine-kinase-like) group of protein kinases and belongs to the Raf kinase family of serine/threonine-specific protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74146 | Raf inhibitor 3 | 1662682-11-2 | Raf inhibitor 3 (Example 30) is a Raf inhibitor. |
|
V2920 | RAF709 | 1628838-42-5 | RAF709 is a novel and potent inhibitor of the Raf kinase B/C isoforms (compound example 131 from patent WO2014151616A1) developed through a hypothesis-driven approach focusing on drug-like properties. |
|
V74148 | SB-682330A | 502498-66-0 | SB-682330A is a Raf kinase inhibitor. |
|
V1008 | SB590885 | 405554-55-4 | SB590885 (SB 590885; SB-590885) is a novel and potent B-Raf inhibitor with potential antineoplastic activity. |
|
V1010 | Sorafenib (Bay 43-9006) | 284461-73-0 | Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN), an approved anticancer drug, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity. |
|
V1003 | Sorafenib Tosylate (Bay 43-9006; Nexavar) | 475207-59-1 | Sorafenib Tosylate (BAY439006; BAY-439006; BAY549085; BAY-549085; Nexavar; SFN), the tosylate salt of Sorafenib which is an approved anticancer medication, is a potent multi-kinase inhibitor of Raf-1, B-Raf and VEGFR-2 with potential antineoplastic activity. |
|
V1012 | TAK-632 | 1228591-30-7 | TAK-632 (TAK 632; TAK632) is a novel and potent pan-Raf inhibitor with potential antineoplastic activity. |
|
V74136 | TBAP-001 | 1777832-90-2 | TBAP-001 (Synthesis 13) information comes from patent WO2015075483A1. |
|
V74134 | Uplarafenib (B-Raf IN 10) | 1425485-87-5 | Uplarafenib (B-Raf IN 10) is a BRAF inhibitor (antagonist) with IC50 in the range of 50-100 nM. |
|
V81731 | Vem-L-Cy5 | Vem-L-Cy5 (compound 3) is a Vemurafenib-based BRAF inhibitor modified with the near-infrared fluorophore cyanine-5 (Cy5). | |
|
V1001 | Vemurafenib (PLX4032; RG7204; RO5185426) | 918504-65-1 | Vemurafenib (formerly PLX-4032; RG7204; RG-7204;RO5185426; RO-5185426;PLX4032; trade name: Zelboraf) is a potent and selective inhibitor of B-RafV600E mutated form with potential antineoplastic activity. |
|
V1009 | ZM 336372 | 208260-29-1 | ZM 336372 (ZM-336372; ZM336372) is a novel, potent and selective c-Raf kinase inhibitor with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
